EphB4 forward signalling mediates angiogenesis caused by CCM3/PDCD10‐ablation
Open Access
- 1 April 2017
- journal article
- Published by Wiley in Journal of Cellular and Molecular Medicine
- Vol. 21 (9) , 1848-1858
Abstract
CCM3, also named as PDCD10, is a ubiquitous protein expressed in nearly all tissues and in various types of cells. It is essential for vascular development and post-natal vessel maturation. Loss-of-function mutation of CCM3 predisposes for the familial form of cerebral cavernous malformation (CCM). We have previously shown that knock-down of CCM3 stimulated endothelial angiogenesis via impairing DLL4-Notch signalling; moreover, loss of endothelial CCM3 stimulated tumour angiogenesis and promoted tumour growth. The present study was designed to further elucidate the inside signalling pathway involved in CCM3-ablation-mediated angiogenesis. Here we report for the first time that silencing endothelial CCM3 led to a significant up-regulation of EphB4 mRNA and protein expression and to an increased kinase activity of EphB4, concomitantly accompanied by an activation of Erk1/2, which was reversed by treatment with the specific EphB4 kinase inhibitor NVP-BHG712 (NVP), indicating that silencing CCM3 activates EphB4 kinase forward signalling. Furthermore, treatment with NVP rescued the hyper-angiogenic phenotype induced by knock-down of endothelial CCM3 in vitro and in vivo. Additional study demonstrated that the activation of EphB4 forward signalling in endothelial cells under basal condition and after CCM3-silence was modulated by DLL4/Notch signalling, relying EphB4 at downstream of DLL4/Notch signalling. We conclude that angiogenesis induced by CCM3-silence is mediated by the activation of EphB4 forward signalling. The identified endothelial signalling pathway of CCM3-DLL4/Notch-EphB4-Erk1/2 may provide an insight into mechanism of CCM3-ablation-mediated angiogenesis and could potentially contribute to novel therapeutic concepts for disrupting aberrant angiogenesis in CCM and in hyper-vascularized tumours.Keywords
Funding Information
- Universität Duisburg-Essen
This publication has 26 references indexed in Scilit:
- Loss of CCM3 impairs DLL4‐Notch signalling: implication in endothelial angiogenesis and in inherited cerebral cavernous malformationsJournal of Cellular and Molecular Medicine, 2013
- The Eph/Ephrin family in cancer metastasis: communication at the service of invasionCancer and Metastasis Reviews, 2012
- Loss of cerebral cavernous malformation 3 ( Ccm3 ) in neuroglia leads to CCM and vascular pathologyProceedings of the National Academy of Sciences, 2011
- Combination of Dll4/Notch and Ephrin-B2/EphB4 targeted therapy is highly effective in disrupting tumor angiogenesisBMC Cancer, 2010
- Differential angiogenesis function of CCM2 and CCM3 in cerebral cavernous malformationsNeurosurgical Focus, 2010
- The small molecule specific EphB4 kinase inhibitor NVP-BHG712 inhibits VEGF driven angiogenesisAngiogenesis, 2010
- Notch1 activation in mice causes arteriovenous malformations phenocopied by ephrinB2 and EphB4 mutantsGenesis, 2010
- Proteomic Identification of the Cerebral Cavernous Malformation Signaling ComplexJournal of Proteome Research, 2007
- The soluble extracellular domain of EphB4 (sEphB4) antagonizes EphB4-EphrinB2 interaction, modulates angiogenesis, and inhibits tumor growthBlood, 2006
- Role of the ephrin and Eph receptor tyrosine kinase families in angiogenesis and development of the cardiovascular systemThe Journal of Pathology, 2006